1. Scrip
  2. >>R&D

Athira’s Fosgonimeton Fails In Phase II/III LIFT-AD Trial, Future Uncertain

Phase I Next-Gen Drug May Become Priority

 
• By Mandy Jackson

The company said that while its drug did not achieve statistical significance on any endpoints in the Alzheimer’s study, improvements favoring fosgonimeton showed potential for HGF modulation.

Mist at the potential end of a road
It's unclear whether the LIFT-AD failure is the end of the road for Athira's drug • Source: Shutterstock

Topline results from the Phase II/III LIFT-AD clinical trial of Athira Pharma, Inc.’s hepatocyte growth factor (HGF) modulator fosgonimeton in mild-to-moderate Alzheimer’s disease show the drug did not achieve statistical significance across any of the study’s primary or secondary endpoints. The company did not shut down development of the drug, but after three mid-stage trial failures, the asset may have reached the end of the road.

Key Takeaways

  • The future of Athira’s HGF modulator fosgonimeton is unclear after it failed in the Phase II/III LIFT-AD clinical trial in mild-to-moderate Alzheimer’s disease.

  • The company will decide what to do with the injectable drug after it shares the trial results with the FDA, but it is continuing development of an earlier oral HGF modulator for ALS

Bothell, WA-based Athira said late on 3 September that it is still considering the path forward for fosgonimeton, which may be determined after the company shares the LIFT-AD results with the US Food and Drug Administration in the coming weeks

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Pipeline Watch: Eight Approvals And Nineteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Leo Roars To A Profit In Q1 As Adbry Grows In US

 
• By Kevin Grogan

The Danish firm's atopic dermatitis drug is holding its own despite strong competition from Sanofi/Regeneron’s Dupixent.

Azafaros Banks Over €130m To Advance Nizubaglustat Into Phase III

 
• By Kevin Grogan

The therapy has been developed for GM1 and GM2 gangliosidoses and Niemann-Pick disease type C.

Lilly Builds Obesity Momentum With New SURMOUNT Data Besting Novo Nordisk

 
• By Alaric DeArment

The presentation and publication of the Phase IIIb study showing greater efficacy for Zepbound over Wegovy come at a time when competition has been heating up between the two obesity medications.

More from R&D

‘Market Developments’ Persuade Galapagos To Rethink Spin-Off

 
• By Andrew McConaghie

CEO Paul Stoffels exits early to be succeeded by Henry Gosebruch, who will now consider ‘all options’ for the Belgian firm as it tries to claw back investor confidence.

Azafaros Banks Over €130m To Advance Nizubaglustat Into Phase III

 
• By Kevin Grogan

The therapy has been developed for GM1 and GM2 gangliosidoses and Niemann-Pick disease type C.

Lilly Builds Obesity Momentum With New SURMOUNT Data Besting Novo Nordisk

 
• By Alaric DeArment

The presentation and publication of the Phase IIIb study showing greater efficacy for Zepbound over Wegovy come at a time when competition has been heating up between the two obesity medications.